Verus Sues AstraZeneca For $1.28B Over Deals To Develop Pediatric Asthma Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Verus claims that it is being “destroyed” by AstraZeneca’s move to terminate a high-value pediatric asthma deal.